136 related articles for article (PubMed ID: 16913845)
1. Transcription factor FOXM1c is repressed by RB and activated by cyclin D1/Cdk4.
Wierstra I; Alves J
Biol Chem; 2006 Jul; 387(7):949-62. PubMed ID: 16913845
[TBL] [Abstract][Full Text] [Related]
2. Cyclin D1/Cdk4 increases the transcriptional activity of FOXM1c without phosphorylating FOXM1c.
Wierstra I
Biochem Biophys Res Commun; 2013 Feb; 431(4):753-9. PubMed ID: 23333330
[TBL] [Abstract][Full Text] [Related]
3. Despite its strong transactivation domain, transcription factor FOXM1c is kept almost inactive by two different inhibitory domains.
Wierstra I; Alves J
Biol Chem; 2006 Jul; 387(7):963-76. PubMed ID: 16913846
[TBL] [Abstract][Full Text] [Related]
4. FOXM1c is activated by cyclin E/Cdk2, cyclin A/Cdk2, and cyclin A/Cdk1, but repressed by GSK-3alpha.
Wierstra I; Alves J
Biochem Biophys Res Commun; 2006 Sep; 348(1):99-108. PubMed ID: 16875671
[TBL] [Abstract][Full Text] [Related]
5. Cyclin E/Cdk2, P/CAF, and E1A regulate the transactivation of the c-myc promoter by FOXM1.
Wierstra I; Alves J
Biochem Biophys Res Commun; 2008 Mar; 368(1):107-15. PubMed ID: 18206647
[TBL] [Abstract][Full Text] [Related]
6. A cyclin D1/cyclin-dependent kinase 4 binding site within the C domain of the retinoblastoma protein.
Pan W; Cox S; Hoess RH; Grafström RH
Cancer Res; 2001 Apr; 61(7):2885-91. PubMed ID: 11306463
[TBL] [Abstract][Full Text] [Related]
7. The transcription factor FOXM1c is activated by protein kinase CK2, protein kinase A (PKA), c-Src and Raf-1.
Wierstra I
Biochem Biophys Res Commun; 2011 Sep; 413(2):230-5. PubMed ID: 21875579
[TBL] [Abstract][Full Text] [Related]
8. Cyclin D1 associates with the TBP-associated factor TAF(II)250 to regulate Sp1-mediated transcription.
Adnane J; Shao Z; Robbins PD
Oncogene; 1999 Jan; 18(1):239-47. PubMed ID: 9926939
[TBL] [Abstract][Full Text] [Related]
9. Deregulation of the cyclin D1/Cdk4 retinoblastoma pathway in rat mammary gland carcinomas induced by the food-derived carcinogen 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine.
Qiu C; Shan L; Yu M; Snyderwine EG
Cancer Res; 2003 Sep; 63(18):5674-8. PubMed ID: 14522882
[TBL] [Abstract][Full Text] [Related]
10. Regulation of the transcription factor FOXM1c by Cyclin E/CDK2.
Lüscher-Firzlaff JM; Lilischkis R; Lüscher B
FEBS Lett; 2006 Mar; 580(7):1716-22. PubMed ID: 16504183
[TBL] [Abstract][Full Text] [Related]
11. Activation of the E2F transcription factor by cyclin D1 is blocked by p16INK4, the product of the putative tumor suppressor gene MTS1.
Schulze A; Zerfass K; Spitkovsky D; Henglein B; Jansen-Dürr P
Oncogene; 1994 Dec; 9(12):3475-82. PubMed ID: 7970707
[TBL] [Abstract][Full Text] [Related]
12. Validation of cyclin D1/CDK4 as an anticancer drug target in MCF-7 breast cancer cells: Effect of regulated overexpression of cyclin D1 and siRNA-mediated inhibition of endogenous cyclin D1 and CDK4 expression.
Grillo M; Bott MJ; Khandke N; McGinnis JP; Miranda M; Meyyappan M; Rosfjord EC; Rabindran SK
Breast Cancer Res Treat; 2006 Jan; 95(2):185-94. PubMed ID: 16319987
[TBL] [Abstract][Full Text] [Related]
13. The central domain of transcription factor FOXM1c directly interacts with itself in vivo and switches from an essential to an inhibitory domain depending on the FOXM1c binding site.
Wierstra I; Alves J
Biol Chem; 2007 Aug; 388(8):805-18. PubMed ID: 17655499
[TBL] [Abstract][Full Text] [Related]
14. Mutual requirement of CDK4 and Myc in malignant transformation: evidence for cyclin D1/CDK4 and p16INK4A as upstream regulators of Myc.
Haas K; Staller P; Geisen C; Bartek J; Eilers M; Möröy T
Oncogene; 1997 Jul; 15(2):179-92. PubMed ID: 9244353
[TBL] [Abstract][Full Text] [Related]
15. Growth inhibition of human MDA-mB-231 breast cancer cells by delta-tocotrienol is associated with loss of cyclin D1/CDK4 expression and accompanying changes in the state of phosphorylation of the retinoblastoma tumor suppressor gene product.
Elangovan S; Hsieh TC; Wu JM
Anticancer Res; 2008; 28(5A):2641-7. PubMed ID: 19035289
[TBL] [Abstract][Full Text] [Related]
16. FOXM1c transactivates the human c-myc promoter directly via the two TATA boxes P1 and P2.
Wierstra I; Alves J
FEBS J; 2006 Oct; 273(20):4645-67. PubMed ID: 16965535
[TBL] [Abstract][Full Text] [Related]
17. Cyclin D1/cdk4 can interact with E2F4/DP1 and disrupts its DNA-binding capacity.
Scimè A; Li L; Ciavarra G; Whyte P
J Cell Physiol; 2008 Mar; 214(3):568-81. PubMed ID: 17894419
[TBL] [Abstract][Full Text] [Related]
18. Involvement of G1/S cyclins in estrogen-independent proliferation of estrogen receptor-positive breast cancer cells.
Bindels EM; Lallemand F; Balkenende A; Verwoerd D; Michalides R
Oncogene; 2002 Nov; 21(53):8158-65. PubMed ID: 12444551
[TBL] [Abstract][Full Text] [Related]
19. Cyclin D1b variant promotes cell invasiveness independent of binding to CDK4 in human bladder cancer cells.
Kim CJ; Nishi K; Isono T; Okuyama Y; Tambe Y; Okada Y; Inoue H
Mol Carcinog; 2009 Oct; 48(10):953-64. PubMed ID: 19415719
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of retinoblastoma protein phosphorylation by myogenesis-induced changes in the subunit composition of the cyclin-dependent kinase 4 complex.
Wang J; Walsh K
Cell Growth Differ; 1996 Nov; 7(11):1471-8. PubMed ID: 8930396
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
